Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain-Gut Axis
- PMID: 25675997
- DOI: 10.1161/ATVBAHA.114.304873
Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain-Gut Axis
Abstract
Objective: Intestinal overproduction of atherogenic chylomicron particles postprandially is an important component of diabetic dyslipidemia in insulin-resistant states. In addition to enhancing insulin secretion, peripheral glucagon-like peptide-1 (GLP-1) receptor stimulation has the added benefit of reducing this chylomicron overproduction in patients with type 2 diabetes mellitus. Given the presence of central GLP-1 receptors and GLP-1-producing neurons, we assessed whether central GLP-1 exerts an integral layer of neuronal control during the production of these potentially atherogenic particles.
Approach and results: Postprandial production of triglyceride-rich lipoproteins was assessed in Syrian hamsters administered a single intracerebroventricular injection of the GLP-1 receptor agonist exendin-4. Intracerebroventricular exendin-4 reduced triglyceride-rich lipoprotein-triglyceride and -apolipoprotein B48 accumulation relative to vehicle-treated controls. This was mirrored by intracerebroventricular MK-0626, an inhibitor of endogenous GLP-1 degradation, and prevented by central exendin9-39, a GLP-1 receptor antagonist. The effects of intracerebroventricular exendin-4 were also lost during peripheral adrenergic receptor and central melanocortin-4 receptor inhibition, achieved using intravenous propranolol and phentolamine and intracerebroventricular HS014, respectively. However, central exendin9-39 did not preclude the effects of peripheral exendin-4 treatment on chylomicron output.
Conclusions: Central GLP-1 is a novel regulator of chylomicron production via melanocortin-4 receptors. Our findings point to the relative importance of central accessibility of GLP-1-based therapies and compel further studies examining the status of this brain-gut axis in the development of diabetic dyslipidemia and chylomicron overproduction.
Keywords: apolipoprotein B-48; central nervous system; chylomicron; glucagon-like peptide-1.
© 2015 American Heart Association, Inc.
Comment in
-
GLP1, an Important Regulator of Intestinal Lipid Metabolism.Arterioscler Thromb Vasc Biol. 2015 May;35(5):1048-9. doi: 10.1161/ATVBAHA.115.305479. Arterioscler Thromb Vasc Biol. 2015. PMID: 25903650 No abstract available.
Similar articles
-
Glucagon-Like Peptide 2 (GLP-2) Stimulates Postprandial Chylomicron Production and Postabsorptive Release of Intestinal Triglyceride Storage Pools via Induction of Nitric Oxide Signaling in Male Hamsters and Mice.Endocrinology. 2015 Oct;156(10):3538-47. doi: 10.1210/EN.2015-1110. Epub 2015 Jul 1. Endocrinology. 2015. PMID: 26132919
-
New and emerging regulators of intestinal lipoprotein secretion.Atherosclerosis. 2014 Apr;233(2):608-615. doi: 10.1016/j.atherosclerosis.2013.12.047. Epub 2014 Jan 21. Atherosclerosis. 2014. PMID: 24534456 Review.
-
GLP1, an Important Regulator of Intestinal Lipid Metabolism.Arterioscler Thromb Vasc Biol. 2015 May;35(5):1048-9. doi: 10.1161/ATVBAHA.115.305479. Arterioscler Thromb Vasc Biol. 2015. PMID: 25903650 No abstract available.
-
Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36.Gastroenterology. 2009 Sep;137(3):997-1005, 1005.e1-4. doi: 10.1053/j.gastro.2009.05.051. Epub 2009 May 29. Gastroenterology. 2009. PMID: 19482026
-
Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states.Curr Opin Lipidol. 2012 Feb;23(1):56-61. doi: 10.1097/MOL.0b013e32834d68f0. Curr Opin Lipidol. 2012. PMID: 22123671 Review.
Cited by
-
Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism.Med Rev (2021). 2024 Apr 10;4(4):301-311. doi: 10.1515/mr-2024-0011. eCollection 2024 Aug. Med Rev (2021). 2024. PMID: 39135603 Free PMC article. Review.
-
Lipoprotein lipase as a target for obesity/diabetes related cardiovascular disease.J Pharm Pharm Sci. 2024 Jul 16;27:13199. doi: 10.3389/jpps.2024.13199. eCollection 2024. J Pharm Pharm Sci. 2024. PMID: 39081272 Free PMC article. Review.
-
Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.Cardiovasc Diabetol. 2018 Apr 4;17(1):48. doi: 10.1186/s12933-018-0689-9. Cardiovasc Diabetol. 2018. PMID: 29618348 Free PMC article.
-
Postprandial Metabolism of Macronutrients and Cardiometabolic Risk: Recent Developments, Emerging Concepts, and Future Directions.Adv Nutr. 2016 Mar 15;7(2):364-74. doi: 10.3945/an.115.010397. Print 2016 Mar. Adv Nutr. 2016. PMID: 26980820 Free PMC article. Review.
-
Bariatric surgery improves postprandial VLDL kinetics and restores insulin-mediated regulation of hepatic VLDL production.JCI Insight. 2023 Aug 22;8(16):e166905. doi: 10.1172/jci.insight.166905. JCI Insight. 2023. PMID: 37432744 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical